ESR1 and breast cancer: It is to be noted that ER-positive (ER+) BC phase-II trials (NCT00676663, NCT00828854, and NCT04190056) are conducted to test whether epi-drugs plus conventional treatments are effective, which indicates that more is known about the epigenetic mechanisms governing the development, migration, and drug resistance of ER+ BC.